Keyword: Intellia Therapeutics
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
Inscripta offers its CRISPR enzymes for free, but the biotech plans to make its money selling CRISPR tools.
A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.
A new journal paper has found that the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system.
Intellia Therapeutics has named John Leonard, M.D., as its new president and chief as former leader and founder Nessan Bermingham, Ph.D., departs.
Khosla Ventures and Seventure Partners have invested in Eligo to equip it to move its lead CRISPR drug toward the clinic in a rare disease.
University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.
Caribou has seen biopharma vet and former Arrowhead exec Steven Kanner join the biotech.
Editas Medicine has delayed the target date for filing an IND for its lead Allergan-partnered CRISPR program.